|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7121 USD | -1.78% |
|
-0.56% | -30.19% |
| Apr. 17 | Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board | CI |
| Apr. 09 | Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target | MT |
Lipella Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 0.118048 million compared to USD 0.033149 million a year ago. Net loss was USD 1.07 million compared to USD 0.73795 million a year ago.
Basic loss per share from continuing operations was USD 0.19 compared to USD 0.19 a year ago. Diluted loss per share from continuing operations was USD 0.19 compared to USD 0.19 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -30.19% | 5.1M | |
| -3.28% | 102B | |
| +1.00% | 96.29B | |
| +1.72% | 22.18B | |
| -15.79% | 21.2B | |
| -9.49% | 18.31B | |
| -38.74% | 17.38B | |
| -13.26% | 16.36B | |
| +5.60% | 13.97B | |
| +33.62% | 12.17B |
LIPELLA PHARMACEUTICALS INC. 
